Skip to main content
. 2005 Dec 1;6:58. doi: 10.1186/1471-2474-6-58

Figure 3.

Figure 3

Primary efficacy endpoints from during the active comparator controlled period (weeks 6 to 52). This is a comparison of etoricoxib 30, 60, and 90 mg with diclofenac 150 mg during the active comparator controlled extension periods. LS Mean Change from Baseline (Randomization) is shown. Modified intention-to-treat approach with last value carried forward was used. The number of patients at later visits (≥34 weeks) was small. Data should, therefore, be interpreted with caution. SE = Standard error. Inline graphic = 30 mg etoricoxib; Inline graphic = 60 mg etoricoxib; Inline graphic = 90 mg etoricoxib; Inline graphic = 150 mg diclofenac.